COVID-19 infection during blinatumomab therapy: Is safety a dilemma?

COVID-19 infection during blinatumomab therapy: Is safety a dilemma?

Patients with acute lymphoblastic leukemia may be particularly vulnerable to SARS-CoV-2 infection and severe illness. The mainstay of current treatment is the use of blinatumomab in patients with refractory or relapsed B-cell precursor acute lymphoblastic leukemia. We discuss the case of a patient w...

Full description

Bibliographic Details
Main Authors:	Julián E Barahona-Correa, Camilo Rueda-Ortiz, María-José López, Sandra Gualtero, Mónica Arevalo-Zambrano
Format:	Article
Language:	English
Published:	SAGE Publishing 2023-01-01
Series:	SAGE Open Medical Case Reports
Online Access:	https://doi.org/10.1177/2050313X221148548

Similar Items

781 Validation of the combinatorial effect of blinatumomab and nivolumab in cancer therapy
by: Jie Zhang, et al.
Published: (2020-11-01)

Blinatumomab in Relapsed/Refractory Burkitt Lymphoma
by: Jeanne Bohler, et al.
Published: (2022-12-01)

The safety of blinatumomab in pediatric patients with acute lymphoblastic leukemia: A systematic review and meta-analysis
by: Maria Maddalena Marrapodi, et al.
Published: (2022-07-01)

Lineage Conversion in Pediatric B-Cell Precursor Acute Leukemia under Blinatumomab Therapy
by: Alexandra Semchenkova, et al.
Published: (2022-04-01)

Relapse and Resistance to CAR-T Cells and Blinatumomab in Hematologic Malignancies
by: Elad Jacoby
Published: (2019-06-01)

Cytofluorimetric assay to investigate variability in blinatumomab in vitro response
by: Stefania Braidotti, et al.
Published: (2022-01-01)

Blinatumomab-induced T cell activation at single cell transcriptome resolution
by: Yi Huo, et al.
Published: (2021-03-01)

Blinatumomab in Pediatric Acute Lymphoblastic Leukemia—From Salvage to First Line Therapy (A Systematic Review)
by: Manon Queudeville, et al.
Published: (2021-06-01)

Blinatumomab Prior to CAR-T Cell Therapy—A Treatment Option Worth Consideration for High Disease Burden
by: Paweł Marschollek, et al.
Published: (2022-11-01)

Use of blinatumomab and CAR T-cell therapy in children with relapsed/refractory leukemia: A case series study
by: Songmi Wang, et al.
Published: (2023-01-01)

Inotuzumab ozogamicin and blinatumomab sequential therapy for relapsed/refractory Philadelphia chromosome-positive acute lymphoblastic leukemia
by: Tomoaki Ueda, et al.
Published: (2022-01-01)

Immunotherapeutic potential of blinatumomab-secreting γ9δ2 T Cells
by: Shang-Ju Wu, et al.
Published: (2023-05-01)

Clinical use of blinatumomab for B-cell acute lymphoblastic leukemia in adults
by: Lee KJ, et al.
Published: (2016-08-01)

Potential for bispecific T-cell engagers: role of blinatumomab in acute lymphoblastic leukemia
by: Le Jeune C, et al.
Published: (2016-02-01)

Reduced‐dose chemotherapy followed by blinatumomab in induction therapy for newly diagnosed B‐cell acute lymphoblastic leukemia
by: Jing Lu, et al.
Published: (2024-03-01)

Blinatumomab as a Bridge Therapy for Hematopoietic Stem Cell Transplantation in Pediatric Refractory/Relapsed Acute Lymphoblastic Leukemia
by: Katarzyna Pawinska-Wasikowska, et al.
Published: (2022-01-01)

Blinatumomab as salvage therapy in patients with relapsed/refractory B-ALL who have failed/progressed after anti-CD19-CAR T therapy
by: Yao Qi, et al.
Published: (2023-12-01)

Efficacy and safety of blinatumomab in children with relapsed/refractory B cell acute lymphoblastic leukemia: A systematic review and meta-analysis
by: Bin Chen, et al.
Published: (2023-01-01)

Positioning blinatumomab in the frontline of adult B-cell acute lymphoblastic leukemia treatment
by: Hoda Pourhassan, et al.
Published: (2023-08-01)

Evaluating blinatumomab implementation in low- and middle-income countries: a study protocol
by: Caitlyn Duffy, et al.
Published: (2022-06-01)

Clinical and pharmacologic aspects of blinatumomab in the treatment of B-cell acute lymphoblastic leukemia
by: Portell CA, et al.
Published: (2013-04-01)

Case Report: Blinatumomab therapy for the treatment of B-cell acute lymphoblastic leukemia patients with central nervous system infiltration
by: Han-Yu Cao, et al.
Published: (2023-04-01)

Results of salvage therapy with mini-hyper-CVD and inotuzumab ozogamicin with or without blinatumomab in pre-B acute lymphoblastic leukemia
by: Hagop Kantarjian, et al.
Published: (2023-05-01)

Successful treatment with blinatumomab for acute lymphoblastic leukemia in an older adult patient complicated with hepatocarcinoma
by: Masuho Saburi, et al.
Published: (2024-01-01)

Short-course blinatumomab for refractory/relapse precursor B acute lymphoblastic leukemia in children
by: Jiao Xie, et al.
Published: (2023-08-01)

Impact of blinatumomab on patient outcomes in relapsed/refractory acute lymphoblastic leukemia: evidence to date
by: Hathaway L, et al.
Published: (2018-10-01)

Complete remission in refractory acute lymphoblastic leukemia using blinatumomab after failure of response to CD‐19 chimeric antigen receptor T‐cell therapy
by: Francesco Paolo Tambaro, et al.
Published: (2020-09-01)

Case Report: Blinatumomab as upfront consolidation and maintenance therapy in a pediatric patient with high-risk B-cell acute lymphoblastic leukemia
by: Sumit Gupta, et al.
Published: (2023-11-01)

Long-Term Follow up of Blinatumomab in Older Patients with B-Cell Acute Lymphoblastic Leukemia
by: Yamini K. Kathari, et al.
Published: (2024-03-01)

Bone marrow necrosis after treatment with blinatumomab for acute lymphoblastic leukemia: A case report
by: Ruihua Mi, et al.
Published: (2024-03-01)

Frontline Blinatumomab in Older Adults with Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia
by: Sandrine Niyongere, et al.
Published: (2020-06-01)

Blinatumomab, a bispecific B-cell and T-cell engaging antibody, in the treatment of B-cell malignancies
by: Richard Burt, et al.
Published: (2019-03-01)

Bispecific T-cell engaging antibodies in B-cell precursor acute lymphoblastic leukemias: focus on blinatumomab
by: Jose-Maria Ribera, et al.
Published: (2020-05-01)

294 Comparison of preclinical efficacy between CD19 CAR-T and CD3×CD19 bispecific antibody (blinatumomab)
by: Jun Huang, et al.
Published: (2023-11-01)

P366: BLINATUMOMAB ADDED TO PREPHASE AND CONSOLIDATION THERAPY IN NEWLY DIAGNOSED PRECURSOR B-ALL IN ADULTS. A PHASE II HOVON TRIAL
by: A. Rijneveld, et al.
Published: (2022-06-01)

RELIABLE FLOW CYTOMETRY METHOD FOR MONITORING OF MINIMAL RESIDUAL DISEASE IN PATIENTS WITH B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA AFTER BLINATUMOMAB THERAPY
by: RM Pontes, et al.
Published: (2023-10-01)

Blinatumomab therapy in a relapsed acute lymphoblastic leukemia with isolated radius involvement following allogeneic bone marrow transplant: a case report
by: İbrahim Halil Açar, et al.
Published: (2020-10-01)

Clinical dilemma of DKA and Covid-19 infection: A case report
by: Margarita Gianniosis, et al.
Published: (2020-01-01)

P372: CMV REACTIVATIONS/INFECTIONS IN PH+ ALL PATIENTS TREATED WITH DASATINIB WITH OR WITHOUT BLINATUMOMAB. A RETROSPECTIVE MULTICENTER CAMPUS ALL STUDY
by: Mario Annunziata, et al.
Published: (2023-08-01)

PB1738: OBSERVATION OF THERAPEUTIC EFFECT OF BLINATUMOMAB SALVAGE TREATMENT ON B – ALL WITH INVALID OR RECURRENT CART
by: Lin Yuehui
Published: (2023-08-01)